An interventional study of Nasal PAP Ventilation System and Low Flow Oxygen in Desaturation, Hypoxemia and ERCP, sponsored by Karl Landsteiner University of Health Sciences. Recruiting at 2 sites in Austria. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-03-24.
Sponsored by Karl Landsteiner University of Health Sciences · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Hypoxia with a site in Austria — 2 open to participants now, 3 under way, none of them phase 3. Hypoxia · Austria.
Among the 12 studies in Hypoxia with a site in Austria, this one is the only one that started in 2025, is one of 7 with no phase, and was the 11th registered.
1,081 studies on the registry are indexed under Hypoxia; 213 are open to participants now.
Browse Hypoxia studies →2 of the 12 studies in Hypoxia with a site in Austria are open now. Recruiting first, the newest first:
Universitaet Innsbruck · Sites in Austria
Ages 18–65 · Healthy volunteers
A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →
Of the 124 Hypoxia studies recruiting now, 52 (42%) set no upper age limit and 46 (37%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2025.
This study's planned enrollment of 288 is above the median of 45 across 771 interventional studies indexed under Hypoxia.
Median enrollment 32 across the 9 interventional studies, 30 across the 3 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 12 has an industry lead sponsor. The 7 most frequent:
Karl Landsteiner University of Health Sciences is the lead sponsor of 13 studies on the registry; 8 are open to participants now.
Karl Landsteiner University of Health Sciences has 1 study filed under Hypoxia — fewer than ten, so there is no comparison to draw.
1 of the studies in Hypoxia with a site in Austria that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07056075Karl Landsteiner University of Health SciencesPrevention of Desaturations Using Positive Airway Pressure or Capnometry During ERCP | 2026-11-30 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies in Hypoxia with a site in Austria, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Although sedation during endoscopy is sufficiently safe, desaturations are among the most common side effects of endoscopic retrograde cholangiopancreatography (ERCP) procedures, occurring in approximately 20-30% of cases. Sedation during endoscopy increases the complication rate, and a significant proportion of severe and serious side effects are respiratory/airway-related. However, most patients require sedation to complete the procedure and achieve adequate outcomes during therapeutic ERCP. Therefore, improved measures to increase ERCP safety are needed. Since the demand for anesthesia in many centers already (far) exceeds current capacities, performing additional ERCPs under general anesthesia is not an option. Innovative ways to improve cardiorespiratory monitoring or respiratory management during ERCP could offer a solution without significantly increasing costs. Fortunately, dedicated devices for respiratory management and/or monitoring during endoscopy already exist, but their impact on improving patient safety has not yet been well studied. Therefore, the aim of this prospective, randomized, open-label, non-interventional study is to investigate the effects of non-invasive airway management and respiratory monitoring devices on desaturation rate during endoscopic retrograde cholangiopancreatography.
For this purpose, 288 adult patients (male and female, 18+ years) undergoing ERCP for medical reasons will be enrolled and randomized to one of three groups: (i) airway management using positive airway pressure (PAP group), (ii) additional monitoring using capnography (capnography group), and (iii) a control group with standard monitoring/treatment (i.e., 2 L O2/min via nasal cannula) (control group). Patients are monitored during the ERCP procedure according to medical standards (non-invasive blood oxygen saturation measurement = SpO2, regular non-invasive blood pressure measurement, pulse), and all desaturation events (defined as an SpO2 \<85% for any duration according to guidelines) are recorded and treated according to guideline recommendations (the studies do not specify any measures for the (non-)treatment of desaturations). After the procedure, patients are followed (passively) for 30 days (review of medical records) to record late complications. The main outcome parameter is the comparison of the desaturation rate in the PAP versus the control group.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Nasal PAP Ventilation System
Device: Nasal PAP Ventilation System
Standard management consisting of low-flow oxygen through nasal cannula
Device: Low Flow Oxygen
capnometry and low-flow oxygen through nasal cannula
Device: Low Flow Oxygen · Device: Capnometry
medical devices that provide nasal positive airway pressure ventilation during endoscopy
Also known as: nasal positive airway pressure
low flow oxygen though nasal cannula
capnometry measurement
Difference in desaturation rate
Differences of rates of desaturations (i.e., SpO2 \<85% for any duration) of the PAP group vs. the standard management group
Time frame: during endoscopic retrograde cholangio-pancreatography
Difference in desaturation rate
Differences of rates of desaturations (i.e., SpO2 \<85% for any duration) across the three groups
Time frame: during endoscopic retrograde cholangio-pancreatography
Difference in desaturation rate
Differences of rates of desaturations (i.e., SpO2 \<85% for any duration) of the capnometry group vs. the standard management group
Time frame: during endoscopic retrograde cholangio-pancreatography
Difference in desaturation rate
Differences of rates of desaturations (i.e., SpO2 \<85% for any duration) of the PAP group vs. the capnometry group
Time frame: during endoscopic retrograde cholangio-pancreatography
Rates of interventions for hypoxemic events
Rates of interventions for hypoxemic events in the PAP group vs. the control group
Time frame: during endoscopic retrograde cholangio-pancreatography
Rates of interventions for hypoxemic events
Rates of interventions for hypoxemic events in the PAP group vs. the capnometry group
Time frame: during endoscopic retrograde cholangio-pancreatography
Rates of interventions for hypoxemic events
Rates of interventions for hypoxemic events in the capnometry group vs. the control group
Time frame: during endoscopic retrograde cholangio-pancreatography
Lowest SpO2
Lowest SpO2 values across the three groups
Time frame: during endoscopic retrograde cholangio-pancreatography
Median procedure length
Median procedure length (min) across the three groups
Time frame: during endoscopic retrograde cholangio-pancreatography
Satisfaction with sedation
Endoscopist and patient satisfaction levels concerning the procedure on a Likert scale ("Satisfaction scale" 0-10, 0=worst, 10=best) across the three groups
Time frame: Periprocedural
Rate of sedation-related adverse events
Rate of sedation-related adverse events across the three groups
Time frame: during endoscopic retrograde cholangio-pancreatography
Rate of SCOPE
Rate of a combined endpoint of serious adverse events and clinical outcomes (SCOPE) across the three groups SCOPE (serious adverse events and clinical outcomes in procedural endoscopy) includes: 30-day all-cause mortality, cardiopulmonary resuscitation1, unplanned intubation or non-invasive ventilation1, single or multiorgan dysfunction due to an endoscopy-related adverse event (AGREE IVa/IVb), rescue or secondary intervention (endoscopic, surgical, or interventional radiology) due to an endoscopy-related adverse event (AGREE IIIa/b), post-ERCP pancreatitis, or target not reached (with necessity of a secondary procedure) 1 AE occurring after start of the procedure (first dose of sedation administered) until patient leaves recovery room.
Time frame: from ERCP up to 30 days after procedure
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2025 (actual). Primary completion is estimated for Nov 2026, 16 months after the start.
Of 324 non-industry interventional studies with no phase under Hypoxia, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 27. This study's planned 16 months is above that.
Counting every sponsor, half of 354 studies reached it within 12 months; a quarter within 3 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Karl Landsteiner University of Health Sciences